Mark Ragosa sold $470k of KNSA
CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc. 20,343 shares at an average of $23.10, traded Mar 17, 2025, filed Mar 19, 2025.
Score components
- +22RoleCFO
- +17Trade size$470k at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.4%, 3m +21.0%, 6m +53.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-008622, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +872 | - | - | 23,830 | Mar 19, 2025 |
| Mar 16, 2025 | FTax withholding Class A Ordinary Share10b5-1 | -448 | $22.61 | $10k | 23,382 | Mar 19, 2025 |
| Mar 17, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +11,464 | $12.97 | $149k | 34,846 | Mar 19, 2025 |
| Mar 17, 2025 | SOpen-market sale Class A Ordinary Share10b5-1 | -11,464 | $23.10 | $265k | 23,382 | Mar 19, 2025 |
| Mar 19, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +8,879 | $12.97 | $115k | 32,261 | Mar 19, 2025 |
| Mar 19, 2025 | SOpen-market sale Class A Ordinary Share10b5-1 | -8,879 | $23.10 | $205k | 23,382 | Mar 19, 2025 |
| Mar 16, 2025 | MOption exercise Restricted Share Unitderivative10b5-1 | -872 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 17, 2025 | MOption exercise Share Optionderivative10b5-1 | -11,464 | $0.00 | $0 | 33,197 | Mar 19, 2025 |
| Mar 19, 2025 | MOption exercise Share Optionderivative10b5-1 | -8,879 | $0.00 | $0 | 24,318 | Mar 19, 2025 |
Related signals
Other insiders at Kiniksa Pharmaceuticals International, plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals International, plc | Michael R Megna CHIEF ACCOUNTING OFFICER | $369k 4,600 shares | -14% | |
| 34Weak | KNSAsell Kiniksa Pharmaceuticals International, plc | G Bradley Cole director | $299k 3,673 shares | -24% | |
| 30Weak | Kiniksa Pharmaceuticals International, plc | John F. Paolini CHIEF MEDICAL OFFICER | $3.1M 58,424 shares | -47% | |
| 50Moderate | Kiniksa Pharmaceuticals International, plc | Sanj K Patel CHAIRMAN & CEO | $2.6M 48,565 shares | -100% | |
| 50Moderate | Kiniksa Pharmaceuticals International, plc | Sanj K Patel CHAIRMAN & CEO | $26M 508,339 shares | -105% | |
| 35Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $656k 13,099 shares | -51% | |
| 29Weak | Kiniksa Pharmaceuticals International, plc | Michael R Megna CHIEF ACCOUNTING OFFICER | $309k 6,625 shares | -19% | |
| 29Weak | Kiniksa Pharmaceuticals International, plc | Ross Moat CHIEF OPERATING OFFICER | $80k 1,703 shares | -12% | |
| 20Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $345k 6,901 shares | -35% | |
| 40Moderate | Kiniksa Pharmaceuticals International, plc | Sanj K Patel CHAIRMAN & CEO | $364k 7,278 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.